For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ORGANIZATION
ORGANIZATION
- JMA Exec Matsumoto Tipped to Replace Adachi as Chuikyo Rep
July 3, 2014
- “No Need to Step Down” as Chair of Biz Lobby, Govt Panel Member: Takeda CEO
July 2, 2014
- Yokokura Reelected as JMA President, 3 Incumbents Retain Veep Seats
July 2, 2014
- Research-Driven Pharmas Could Diverge into 2 Groups Based on Dependence on Off-Patent Drugs: FPMAJ Chair
July 1, 2014
- Min-Iren Urges Novartis to Return “Unfair Profits”
June 24, 2014
- JMA President Yokokura to Serve Second Term
June 20, 2014
- Japan Diabetes Group Announces Recommendations on Proper Use of SGLT-2 Inhibitors
June 17, 2014
- Daiichi Sankyo Pres. Nakayama Elected as New President of PMAT
June 17, 2014
- New Price Cut Rule Barring Generic Replacement of Long-Listed Products: FPMAJ
June 17, 2014
- US-Japan Business Council Airs Concerns over Annual NHI Price Revision
June 13, 2014
- Member Companies Conducted 682 Clinical Trials in Japan in 2013: PhRMA/EFPIA
June 11, 2014
- Generic Versions of Combination Drug Exforge to Be Named “Amvalo”: JSGM
June 10, 2014
- Santen President Officially Becomes New OPMA Head
May 29, 2014
- FPMAJ, JPMA Issue Joint Statement Opposing Once-Yearly NHI Price Revision
May 29, 2014
- JPWA Chief Highlights Progress in Single-Product, Single-Price Trading
May 27, 2014
- MTPC, MSD Return to JPMA’s BOD
May 26, 2014
- Yearly NHI Price Revision Not Consistent with Growth Strategy: JPMA Exec
May 23, 2014
- Astellas Chair Nogimori Sworn in as Head of FPMAJ
May 22, 2014
- Dainippon Pres. Tada Elected New Chief of JPMA
May 22, 2014
- Market Share of Generic Drugs Based on New Calculation Method Rose to 44.9% in 3rd Quarter of FY2013: JGA
May 19, 2014
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…